EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Streamlining Genetically Modified Organism Regulatory Classification in UK Gene Therapy Clinical Trials: A UK Pharmacy Perspective

Annalisa Del Prete iD, Beatriz Duran Jimenez, Anne Black

Human Gene Therapy · 12.08.2026

DOI: 10.1177/10430342261473434 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Gene Therapy, online erschienen am 12.08.2026. Verfasst von Annalisa Del Prete und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurate classification of Genetically Modified Organism (GMO) gene therapies remains a significant challenge to initiating clinical trials in the United Kingdom, often delaying patient access to innovative treatments. Current regulatory processes require separate GMO risk assessments at each National Health Service (NHS) trial location, leading to inconsistent approaches and duplication of effort. This article presents the development of a decision tree designed to streamline GMO classification for Gene Therapy Investigational Medicinal Products (GTIMPs). The proposed tool aims to address key challenges in trial setup by providing a structured and evidence-based approach to GMO classification, clarifying international misalignment in hazard classification and offering practical guidance for the in vivo and ex vivo GMO GTIMPs most encountered in clinical practice. By harmonizing decision-making and clarifying containment requirements, the adoption of the decision tree across NHS organizations could reduce variability, accelerate trial setup, and strengthen the United Kingdom’s position as a competitive destination for GTIMP clinical trials.

Schlagwörter

Stichwörter der Autor:innen

GMO activity classificationGMO risk assessment harmonizationGene Therapy Investigational Medicinal Products (GTIMPs)Genetically Modified Organisms (GMO)NHS clinical practiceUK clinical trials

Autor:innen und Institutionen

  • Pharmacy Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • Pharmacy Department, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • NHS Specialist Pharmacy Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom.

ORCID-Profile: Annalisa Del Prete

Zitieren

APA

Del Prete, A., Duran Jimenez, B., & Black, A. (2026). Streamlining Genetically Modified Organism Regulatory Classification in UK Gene Therapy Clinical Trials: A UK Pharmacy Perspective. Human Gene Therapy. https://doi.org/10.1177/10430342261473434

Vancouver

Del Prete A, Duran Jimenez B, Black A. Streamlining Genetically Modified Organism Regulatory Classification in UK Gene Therapy Clinical Trials: A UK Pharmacy Perspective. Human Gene Therapy. 2026. doi:10.1177/10430342261473434

BibTeX
@article{DelPrete2026,
  author = {Del Prete, Annalisa and Duran Jimenez, Beatriz and Black, Anne},
  title = {Streamlining Genetically Modified Organism Regulatory Classification in UK Gene Therapy Clinical Trials: A UK Pharmacy Perspective},
  journal = {Human Gene Therapy},
  year = {2026},
  doi = {10.1177/10430342261473434}
}
Kostenlos starten →